1. Home
  2. SKYE vs NBY Comparison

SKYE vs NBY Comparison

Compare SKYE & NBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.77

Market Cap

27.1M

Sector

Health Care

ML Signal

HOLD

Logo NovaBay Pharmaceuticals Inc.

NBY

NovaBay Pharmaceuticals Inc.

HOLD

Current Price

$1.95

Market Cap

31.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKYE
NBY
Founded
2012
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.1M
31.6M
IPO Year
2013
2007

Fundamental Metrics

Financial Performance
Metric
SKYE
NBY
Price
$0.77
$1.95
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$15.00
N/A
AVG Volume (30 Days)
178.4K
608.2K
Earning Date
05-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
35.42
EPS
N/A
0.76
Revenue
N/A
$370,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$2.57
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$0.43
52 Week High
$5.75
$19.95

Technical Indicators

Market Signals
Indicator
SKYE
NBY
Relative Strength Index (RSI) 48.42 57.82
Support Level $0.70 $1.01
Resistance Level $0.83 $2.52
Average True Range (ATR) 0.06 0.26
MACD -0.00 0.11
Stochastic Oscillator 51.56 96.45

Price Performance

Historical Comparison
SKYE
NBY

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About NBY NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.

Share on Social Networks: